Four former FDA commissioners on Thursday (March 16) urged Congress not to move forward with drug importation, which has been eyed by both President Donald Trump and members of Congress as a drug pricing solution, on the grounds that allowing drug imports would pose safety risks, strain FDA resources and do little to bring down costs. Trump's pick to head FDA also previously said the amount of agency oversight needed to prevent entry of fake drugs would zero out any...